Targeting Cystic Fibrosis Using A Novel Inhalation Therapy
Funder
National Health and Medical Research Council
Funding Amount
$421,545.00
Summary
Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.
I am a matrix biologist determining the molecular mechanisms and novel therapeutic targets for fibrosis (tissue scarring). In particular, my research, which has a strong translational focus, is involved with elucidating the anti-fibrotic potential of the relaxin peptide-hormones (either alone or as an adjunct therapies to existing/other novel treatments) – as a means of developing therapeutic strategies for the treatment of cardiac and renal fibrosis.